Narrative review explores emerging therapeutic strategies targeting Th17 and Treg balance in systemic lupus erythematosus

This publication is classified as a narrative review focusing on systemic lupus erythematosus. The authors synthesize information regarding emerging therapeutic strategies aimed at restoring the Th17 and Treg balance. The review does not report a specific sample size, setting, or follow-up duration. It serves as a conceptual overview rather than a systematic analysis of primary trial data.

Several medication classes are highlighted within the discussion. These include IL-17 inhibitors, IL-6 receptor antagonists, low-dose IL-2, mammalian target of rapamycin inhibitors, chimeric antigen receptor T-cell, and CAR-Treg. The text outlines these agents as potential interventions for the specified population of patients with SLE. No comparator is explicitly defined in the source material provided.

The central argument revolves around immunomodulation through the restoration of specific immune cell balances. The authors present these strategies as emerging options rather than established standards of care. Because main results are not reported, specific efficacy outcomes or pooled effect sizes are absent from this summary. The narrative does not quantify the magnitude of potential clinical benefit.

Safety data and tolerability profiles are not reported in this review. Serious adverse events and discontinuations are also not reported. The authors do not provide a certainty note or causality note regarding the findings. Practice relevance is not reported, limiting the ability to draw immediate clinical conclusions. Consequently, the evidence remains early and uncertain for current practice guidelines.

Limitations regarding the review structure are not explicitly listed by the authors.